Silver

Silverback Therapeutics was a clinical-stage biopharmaceutical company focused on developing a proprietary pipeline of ImmunoTAC (Immuno-Targeted Antibody Conjugate) therapies. The company's platform was designed to deliver potent small molecule payloads, such as Toll-like receptor (TLR) agonists, specifically to the tumor microenvironment or other sites of disease while minimizing systemic toxicity. Its lead candidate, SBT6050, targeted HER2-expressing solid tumors by activating myeloid cells to trigger an anti-tumor immune response. In 2022, Silverback Therapeutics completed a reverse merger with ARS Pharmaceuticals, transitioning the combined entity's focus toward ARS's emergency allergy treatments.